Skip to main content

Table 1 Comparison of baseline patient characteristics between different stages of the flowchart as presented in Fig. 1

From: Improvement of symptoms in clinically suspect arthralgia and resolution of subclinical joint inflammation: a longitudinal study in patients that did not progress to clinical arthritis

Patient characteristicsN = 241N = 196N = 152N = 98
Age in years, mean (SD)44 (13)44 (13)45 (13)47 (13)
Female sex, N (%)187 (78)152 (77)118 (78)73 (74)
Family history of RA, N (%)71 (30)52 (27)43 (28)28 (29)
Symptom duration in weeks, median (IQR)18 (10–48)17 (9–30)17 (9–33)17 (9–43)
Presence of morning stiffness ≥ 60 min, N (%)80 (33)61 (35)49 (32)29 (30)
68-TJC, median (IQR)6 (3–10)6 (2–11)6 (2–10)5 (2–10)
VAS pain score, median (IQR)5 (3–7)5 (3–7)5 (3–7)5 (3–6)
 3 items on EULAR definition of arthralgia suspicious for progression to RA [13], N (%)178 (74)141 (72)100 (66)63 (64)
Increased CRP (≥ 5 mg/L), N (%)53 (22)39 (20)29 (19)19 (19)
Autoantibody status
 Negative for IgM-RF and ACPA, N (%)184 (76)166 (84)125 (82)79 (81)
 ACPA- or RF-positive, N (%)57 (24)31 (16)27 (18)19 (19)
  1. ACPA anti-citrullinated peptide antibody (positive if ≥ 7 U/mL), CRP C-reactive protein, IgM-RF immunoglobulin M rheumatoid factor (positive if ≥ 3.5 IU/mL), IQR interquartile range, RA rheumatoid arthritis, SD standard deviation, TJC tender joint count